Numinus to Participate in Citi's Psychedelic Drug Call Series on February 2, 2022
Numinus Wellness (TSX: NUMI) (OTC: NUMIF), a leader in mental health care, announced its participation in Citi's Psychedelic Drug Call Series on February 2, 2022. The event will feature a fireside chat between Payton Nyquvest, Founder and CEO of Numinus, and Neena Bitritto-Garg, Citi's Biotech analyst, at 10:00 a.m. ET. Numinus focuses on psychedelic-assisted therapies to improve mental health outcomes for conditions like depression and anxiety. More details are available on Numinus' website.
- None.
- None.
VANCOUVER, BC, Jan. 25, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Citi's Psychedelic Drug Call Series to be hosted virtually on Wednesday, February 2, 2022.
Neena Bitritto-Garg, Citi's Biotech analyst, will host Payton Nyquvest, Founder and CEO of Numinus, for a fireside chat at 10:00 a.m. ET.
For more information about the event, please contact your appropriate Citi representative directly, or KCSA Strategic Communications at NuminusIR@kcsa.com.
About Numinus
Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's limited operating and profitability track record; dependence on management; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.
View original content:https://www.prnewswire.com/news-releases/numinus-to-participate-in-citis-psychedelic-drug-call-series-on-february-2-2022-301467505.html
SOURCE Numinus Wellness Inc.
FAQ
What is Numinus Wellness participating in on February 2, 2022?
Who will lead the fireside chat for Numinus at the event?
What time does the Numinus event start on February 2, 2022?
How does Numinus Wellness contribute to mental health care?
Where can I find more information about Numinus Wellness?
